LEO Pharma and X-Chem Enter Into Discovery Research Agreement
Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications
BALLERUP, Denmark, and WALTHAM, Mass., US; July 6, 2021 – LEO Pharma A/S, a global leader in medical dermatology and X-Chem, Inc., the global leader in DNA-encoded library (DEL) driven discovery solutions, announced today that they have entered into a research collaboration and license agreement. The goal of the collaboration is to discover and develop novel treatments for dermatological indications.
Under the terms of the agreement, X-Chem will deploy its proprietary DEL platform to identify novel drug-like leads against multiple inflammation targets of interest to LEO Pharma. LEO Pharma has the option to receive exclusive global rights to compounds derived from the partnership and will be responsible for preclinical and clinical research and development. LEO Pharma also retains all rights to commercialization of any potential new medicines emerging from the collaboration.
“At LEO Pharma, we are dedicated to changing the standards of care for people with skin diseases by bringing new innovative treatments forward that are either first or best in class. Supporting this ambition, we are excited to work with the X-Chem team to identify novel small molecule drug leads,” said Thorsten Thormann, Head of Research and early Development. “X-Chem’s DEL platform technology is a powerful approach giving us increased capabilities to feed our innovative project portfolio.”
X-Chem CEO Matt Clark, Ph.D., said, "We are delighted to partner with LEO Pharma, a global leader in medical dermatology R&D. We look forward to a productive partnership with many tractable drug leads.”
+45 3140 6180
Steffen Helmling, PhD
+1 781 4196900
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million. For more information please visit www.LEO-Pharma.com.
X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. X-Chem empowers partners to rapidly screen billions of diverse, drug-like compounds simultaneously and easily identify potent hits that exhibit desired selectivity and mode of action with attractive physicochemical properties. In-house lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification.
For more about X-Chem, visit x-chemrx.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma successfully refinances loan facility15.11.2021 08:00:00 CET | Press release
Ballerup, November 15, 2021 – Today, LEO Pharma announced that it has successfully refinanced the company’s syndicated loan facility of total DKK 11.2 billion.
Adtralza® (tralokinumab) achieves primary and secondary endpoints in Phase 3 trial of adolescents with moderate-to-severe atopic dermatitis22.10.2021 13:00:00 CEST | Press release
Sixteen-week results from the Phase 3 ECZTRA 6 trial in adolescents showed tralokinumab 150 mg and 300 mg significantly improved measures of efficacy compared to placebo1 Tralokinumab was generally well-tolerated with an overall frequency and severity of adverse events comparable with placebo, consistent with that observed in adults in Phase 3 trials1 BALLERUP, Denmark, October 22, 2021 – LEO Pharma A/S, a global leader in medical dermatology, today announced 16-week results of a 52-week monotherapy trial showing tralokinumab significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.1 The week 16 results from the Phase 3 ECZTRA 6 trial were shared during the 2021 Fall Clinical Dermatology Conference held virtually and with a hybrid option in Las Vegas. Tralokinumab is a high-affinity, human monoclonal antibody that specifically binds to and inhibits IL-13, a key driver of atopic dermatitis signs and
LEO Pharma presents new Adtralza® (tralokinumab) data following long-term continuous treatment at EADV 30th Congress30.9.2021 10:40:00 CEST | Pressemeddelelse
• Interim analysis of ECZTEND, an open-label extension trial, demonstrated sustained improvements in extent and severity of atopic dermatitis after two years of continuous treatment, with a 92.7% median EASI improvement from parent trial baseline1 • Patients also reported improvements in itch severity and sleep interference1
LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials29.9.2021 14:00:00 CEST | Press release
Connected solution aims to deliver faster trials and a better patient experience BALLERUP, DENMARK and PLEASANTON, CA — Sept. 29, 2021 — LEO Pharma, a global leader in medical dermatology, and Veeva Systems (NYSE: VEEV) today announced a strategic technology partnership to enable scalable digital trials that are patient-centric and paperless.
Jesper Brandgaard ny formand for LEO Pharmas bestyrelse1.7.2021 13:00:00 CEST | Pressemeddelelse
Jesper Brandgaard bliver ny formand for LEO Pharmas bestyrelse. Han afløser Olivier Bohuon.
LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis22.6.2021 08:00:00 CEST | Press release
NOT FOR DISTRIBUTION IN THE UK OR IRELAND BALLERUP, Denmark, JUNE 22, 2021 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Commission (EC) has approved Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The European approval makes Adtralza the first high affinity, fully human monoclonal antibody approved to specifically bind to and inhibit the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,4,5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom